Fluence LED Solutions Pave the Way for Optimizing Success in Urban Medicinal Cannabis Grow
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its success in supporting Trichome, an Israeli facility growing world-class medicinal cannabis, to prove the concept of two-tiered vertical farming in an urban center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005315/en/
Fluence LEDs inside Trichome's urban facility have supported 17 full crop growing cycles, all with greater than expected results. (Photo: Business Wire)
To successfully launch an urban vertical growing facility in Qiryat Gat, Israel, Trichome needed to collaborate with the right solution partners to maximize space while optimizing quality and automation at every step of the process. To appropriately design for the compact, intricate indoor environment and complexities associated with tiered growing, Trichome turned to Fluence for its market-leading LED lighting solutions, local service capabilities through Fluence's Israeli distribution partner, REMY, and in-house horticultural experts to assist with planning, installing and managing the deployment of integrated lighting technology.
“By partnering with Fluence, we were not reinventing the wheel but choosing the best wheels in the market,” said Tony Levi, co-founder and CEO of Trichome. “Standardization, longevity and optimization are critical factors in producing high-quality cannabis flowers. The team of experts at Fluence helped us accomplish all of those goals in an urban farm within city limits.”
Trichome installed Fluence lighting throughout its fully standardized medicinal cannabis facility. To overcome the obstacles presented by a reduction in space between crops and the artificial lights in vertical farms, Fluence worked closely with REMY, Levi and the Trichome team to understand the facility’s constraints. Ultimately, Fluence designed a bespoke system comprising its SPYDR 2i, SPYDR 2x and RAZR Modular series for Trichome. Trichome has completed 17 full crop growing cycles, all with greater than expected results using Fluence lighting—including above average yields, higher than expected terpene levels and high cannabinoid content.
“We are thrilled by the response of our plants to the Fluence LED lighting,” said Steve Abboud, head grower at Trichome. “Our cannabis crops are taking in the light from Fluence fixtures and expressing its quality through their flowering. We have been able to standardize light intensity, harness control over our cultivation methods and achieve crop uniformity because of Fluence LEDs.”
“Working with Trichome on lighting solutions has been an exciting and ambitious process where both parties learned a tremendous amount,” said Jörg Meyer-Brenken, lead account manager, cannabis EMEA at Fluence. “The product Trichome supplies is outstanding, but the feedback from the market and patients makes me even prouder. Trichome has been able to set a new bar for urban farming.”
Fluence LED lighting solutions are available for purchase by licensed cultivators in territories in which the cultivation of cannabis is legal.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, today, it also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
About Trichome
Trichome is an Israeli agritech company that combines two complementary worlds—quality cannabis agriculture and advanced cannabis technologies. The company philosophy is based on three main pillars: Indoor Growth by Advanced Technology, an international team of cannabis experts and the finest, high-end varieties. Trichome owns the largest Indoor facility for medical cannabis cultivation in the Middle East. With nine flowering rooms, the multilayer facility is spread over 7,000 square meters and has an annual production capacity of six tons of high-quality, consistent standardized inflorescence. Trichome works through several channels including its own brand and white label. For more information, visit www.trichome-il.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005315/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (0) 160 93335045
For North America,
Callie Neatherlin
Red Fan Communications
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
